AI Technology & Industry Review
In the new paper Unlocking de Novo Antibody Design With Generative Artificial Intelligence, researchers from Absci Corporation leverage the power of generative artificial intelligence for de novo antibody design in a zero-shot and controllable manner, dramatically reducing time and resource requirements for the task.
Researchers analyzed different subareas of CADD process with a focus on anticancer drugs.
A new study leverages an established AI-based drug discovery pipeline to produce molecular structures as part of the widening fight against the 2019-nCoV outbreak.
The crucial step now is to develop matching vaccines and drugs to uproot its existence, and China’s big tech companies have stepped up to help.
Insilico Medicine, a drug discovery startup located in Johns Hopkins University, has introduced MOSES (Molecular Sets), a platform which can be used to compare model accuracy in molecular generation. MOSES provides a standardized benchmarking dataset, a set of open-sourced models with unified implementation, and evaluation metrics.
In December 2017 Chinese pharma tech startup AccutarBio raised US$15 million from IDG Capital, YITU Tech, and ZhenFund.
The US FDA defines five steps for the development of a new drug: discovery and development, preclinical research, clinical research, FDA review, and FDA post-market safety monitoring.